LoadingLoadingLoadingThe quick read
Latest quote
Net selling: insiders sold $8.3M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $8.3M and bought $0 of DGX stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. $8.3M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Prevoznik, Michael E (SVP & General Counsel), who sold $5.5M. The latest filing was on Sep 3, 2026.
None. No member of Congress disclosed a DGX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
Balyasny
$57.8M
added
Sells/Trims (2)
Qube Research
$71.2M
trimmed
Squarepoint
$42.8M
trimmed
Buys (1)
Sells (2)
No tracked top-trader positions in DGX right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Jul 23, 2026
Financial period
Q2 2026
Earnings per share
$2.81 expected
Revenue
No comparable estimate
FY2026 guidance
$11.95B to $12.05B
No comparable estimate
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Jul 23, 2026 | $3.12 / $2.81Alpha Vantage | +11.03% beat | $3.04B / Unavailable | Unavailable |
| Mar 31, 2026 | Apr 21, 2026 | $2.50 / $2.37Alpha Vantage | +5.49% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 10, 2026 | $2.42 / $2.36Alpha Vantage | +2.54% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Oct 21, 2025 | $2.60 / $2.50Alpha Vantage | +4.00% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Jul 22, 2025 | $2.62 / $2.57Alpha Vantage | +1.95% beat | Unavailable | Unavailable |
| Mar 31, 2025 | Apr 22, 2025 | $2.21 / $2.15Alpha Vantage | +2.79% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Jan 30, 2025 | $2.23 / $2.18Alpha Vantage | +2.29% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Oct 22, 2024 | $2.30 / $2.26Alpha Vantage | +1.77% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Estimates as of Oct 17, 2026
EPS expected
$2.82 to $2.94
Revenue expected
12 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $2.82B | $2.81B | $2.90B | $3.04B |
| Cost of what it sold | $1.87B | $1.89B | $1.95B | $2.02B |
| Gross profit | $949.0M | $914.0M | $942.0M | $1.03B |
| What it spent | ||||
| Sales and admin | $501.0M | $486.0M | $504.0M | $529.0M |
| Other operating costs | $62.0M | $37.0M | $39.0M | $39.0M |
| Total operating expenses | $563.0M | $523.0M | $543.0M | $568.0M |
| What was left | ||||
| Operating profit | $386.0M | $391.0M | $399.0M | $459.0M |
| Interest on debt | $69.0M | $67.0M | $63.0M | $63.0M |
| Profit before tax | $336.0M | $337.0M | $334.0M | $412.0M |
| Tax | $77.0M | $81.0M | $74.0M | $88.0M |
| Net profit | $245.0M | $245.0M | $252.0M | $320.0M |
| EBITDA | $547.0M | $546.0M | $544.0M | $589.0M |
This stock is trending upward.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Quest Diagnostics Incorporated (DGX) Options Chain - Yahoo Finance
NeutralOct 15Needham sets USD 22.00 target for NeoGenomics stock
NeutralOct 15MiniMed Announces Board of Directors for its Next Chapter as an Independent Company
NeutralOct 15OraSure Technologies stock trades above USD 3.00 consensus target
NeutralOct 15Raymond James keeps USD 95.00 target for RadNet stock
NeutralOct 15NeoGenomics, Inc. (NEO) Stock Forecasts
NeutralOct 15Truist lifts target to USD 260.00 for Quest Diagnostics stock
Leans bullishOct 15Truist boosts target for Labcorp stock to USD 365.00
NeutralOct 15